M. Meergans

发表

Downregulation of β-adrenergic receptors by low density lipoproteins and its prevention by β-adrenergic receptor antagonists

K. Karsch, D. Axel, B. Brehm, 1998 .

Downregulation of beta-adrenergic receptors by low density lipoproteins and its prevention by beta-adrenergic receptor antagonists.

K. Karsch, D. Axel, B. Brehm, 1998, Cardiovascular Research.

Interferon-β1b in der Multiple-Sklerose-Therapie

H. Hartung, M. Meergans, J. Haas, 2013, Der Nervenarzt.

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab

Achim Gass, Tjalf Ziemssen, Judith Haas, 2016, BMC Neurology.

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

D. Arnold, S. Shang, M. Meergans, 2018, Therapeutic advances in neurological disorders.

Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients

M. Baier, M. Meergans, M. Mäurer, 2013, Multiple sclerosis.

Fingolimod-Compassionate-use-Programm

H. Hartung, M. Meergans, S. Ortler, 2012, Der Nervenarzt.

Interim Results of the PANGAEA and PEARL Studies, Comparing Treatment Satisfaction and Pharmaco-Economic Data of Fingolimod (Gilenya®) and First-Line Therapies in Multiple Sclerosis Patients in Germany (P03.220)

P. Vollmar, T. Ziemssen, M. Meergans, 2013 .

Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia

M. Meergans, S. Kılıçkap, M. Ouda, 2023, Cureus.